Imaging One Week After Immunotherapy May Predict Treatment Response in Advanced Melanoma

F-fluorodeoxyglucose (FDG) PET/CT imaging of tumors in patients with advanced melanoma receiving pembrolizumab (Keytruda, Merck) after just one week may predict treatment response, according to a study in Clinical Cancer Research. Typically, these immunotherapy patients are imaged around three months after starting treatment to monitor their progress. For the study, Michael D. Farwell, MD, an associate […]